A new market study, titled “Global Gene Therapy Market by Manufacturers, Countries, Type and Application, Forecast to 2023”, has been featured on WiseGuyReports.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson’s disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
Scope of the Report:
This report studies the Gene Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy market by product type and applications/end industries.
Gene therapy is a method that involves introducing genetic material into a person’s cells to fight or prevent diseases. In recent decades of years, researchers are paying more and more attention on it. Until today, it is still in infancy. There are many bio-technology companies entered into this market and carry on related research and development.
These research companies are including Bluebird Bio, Sangamom, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical and Advantagene. Among them, the top 5 research companies occupied more than 85% market.
Generally, the research fees of companies are come from their collaboration partners. For example, Bayer Healthcare is the partner of Dimension Therapeutics. General, some products of these companies are in the period 3 of their pipeline.
In general, cancer diseases are still the largest application with market share over 65% in 2015. In addition, there are some companies are focus on rare diseases.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy.
Market Segment by Companies, this report covers
Bluebird Bio
Sangamo
Spark Therapeutics
Dimension Therapeutics
Avalanche Bio
Celladon
Vical Inc.
Advantagene
Request Sample Report at https://www.wiseguyreports.com/sample-request/3257910-global-gene-therapy-market-by-manufacturers-countries-type
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Ex vivo
In Vivo
Market Segment by Applications, can be divided into
Cancer
Monogenic
Infectious disease
Cardiovascular disease
Other
Table of Contents
1 Gene Therapy Market Overview
2 Manufacturers Profiles
3 Global Gene Therapy Market Competition, by Players
4 Global Gene Therapy Market Size by Regions
5 North America Gene Therapy Revenue by Countries
6 Europe Gene Therapy Revenue by Countries
7 Asia-Pacific Gene Therapy Revenue by Countries
8 South America Gene Therapy Revenue by Countries
9 Middle East and Africa Revenue Gene Therapy by Countries
10 Global Gene Therapy Market Segment by Type
11 Global Gene Therapy Market Segment by Application
12 Global Gene Therapy Market Size Forecast (2018-2023)
13 Research Findings and Conclusion
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
